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ABSTRACT
 
Several years experience has now been gained in the use
of needs-based measures in clinical trials and such use is
increasing rapidly. This paper shows how four needs-
based quality of life (QoL) instruments have proved
effective in determining the beneﬁts of interventions
from the patients’ perspective in clinical studies and tri-
als. The instruments discussed are; the Quality of Life in
Depression Scale (QLDS), the Migraine Speciﬁc Quality
of Life Scale (MSQoL), the Recurrent Genital Herpes
Quality of Life (RGHQoL), and the Quality of life—
Assessment in Growth Hormone Deﬁcient Adults
(QoL-AGHDA).
Keywords: adult growth hormone deﬁciency, depression,
migraine, quality of life, recurrent genital herpes.
 
Introduction
 
Since 1992 the needs-based quality of life (QoL)
model proposed by Hunt and McKenna [1] has
formed the basis of 20 disease-speciﬁc QoL instru-
ments developed by researchers in the UK and the
US. The content of each of these instruments was
developed directly from interviews with relevant
patients. Consequently, items reﬂect the concerns of
the patients rather than those of investigators. The
measures  are  easy  to  administer  and  complete
and are well accepted by both investigators and
respondents. All language versions of the instru-
ments developed have better psychometric qualities
than many of the available health-related quality of
life (HRQL) instruments. For example, all 11 lan-
guage versions of the Quality of Life in Depression
Scale display test–retest reliability values above
0.90, a crucial indicator of the instrument’s respon-
siveness and construct validity [2]. Test–retest reli-
ability of the scales in the SF-36 has been reported
in ﬁve studies [3–7]. Of the 40 estimates provided, 2
were 0.90 or above and only 6 reached the mini-
mum required for use in a clinical trial (0.85 [8]).
Reliability estimates observed for the main Euro-
pean generic health status questionnaire, the Not-
tingham Health Proﬁle (NHP), while higher than
those for the SF-36, also generally fail to reach an
adequate level [9].
This paper provides examples of how four needs-
based QoL instruments have proved responsive
(able to detect real change in QoL) in clinical stud-
ies. In the absence of other disease-speciﬁc QoL
instruments, the performance of the needs-based
instrument is usually compared with that of the SF-
36. It is not intended to be critical of this particular
instrument but reﬂects the fact that its use is ubiq-
uitous in health-outcomes research. There is little
doubt that similar measures such as the Nottingham
Health Proﬁle [9] and Sickness Impact Proﬁle [10]
would be shown to be similarly limited in their abil-
ity to provide useful information in the context of
clinical studies and trials.
 
Quality of Life in Depression
 
The Quality of Life in Depression Scale (QLDS) was
the ﬁrst needs-based QoL measure [11]. It has been
widely adapted for use throughout Europe and the
Americas [2] and has been used in several clinical
trials and studies. Two of these studies reported on
the responsiveness of the QLDS [12,13]. These were
open-label general practice studies with patients fol-
lowed up for 8 weeks following initiation of treat-
ment with ﬂuoxetine. Scores on the QLDS were
closely related to severity of depression as deter-
mined by the Hamilton Depression Rating Scale, as
shown in Table 1 [13]. Mean scores on the QLDS
for the 133 patients who completed the study fell
from 22.0 to 5.2. In the Grégoire et al. study [12]
patients were aged 60 years or above (
 
n
 
 
 
=
 
 196). A
similar improvement in scores was found
(mean 
 
=
 
 23.1 at baseline and 8.4 after 8 weeks).
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This equated to effect sizes of 1.93 and 1.92, respec-
tively. Such values are rarely achieved in clinical
studies with an effect size of 1.0 being considered
large. Walker and colleagues [14] undertook an
identical study with moclobemide, which they
reported to be a more effective antidepressant than
ﬂuoxetine. Effect sizes for the eight SF-36 subscales
(the outcome measure selected in the study) ranged
from 0.12 to 0.71.
 
Migraine Speciﬁc Quality of Life
 
The superior responsiveness of a needs-based
instrument was clearly shown in a study comparing
the performance of the Migraine Speciﬁc Quality
of Life Scale (MSQoL) and the SF-36 with 1383
migraineurs treated with zolmitriptan [15]. The
MSQoL is employed to determine changes over
time in a patient’s QoL resulting from effective
treatment of their migraine. It is completed between
headaches and is not concerned with the symptoms
or disability associated with the attack itself. It is
hypothesized that as a patient gains conﬁdence that
they are receiving an effective treatment, their QoL
will improve. This hypothesis was supported by the
ﬁnding that MSQoL score improvements were sig-
niﬁcantly greater among patients who responded to
treatment at 2 hours than those who did not.
The effect size for the MSQoL was 0.25 and that
for the eight SF-36 scales averaged 0.03. These dif-
ferences in responsiveness are considerable and
could account for the improvements in MSQoL
scores being statistically signiﬁcant while those for
the SF-36 were not.
 
Quality of Life in Recurrent Genital Herpes
 
Patel and colleagues [16] reported on the impact of
suppressive antiviral therapy on the QoL of patients
with recurrent genital herpes (RGH). As with
migraine, the QoL issue was whether treatment that
prevents or reduces the number or severity of out-
breaks improves the overall QoL of the patient.
Again the concern was not with the experience of an
outbreak—a recent instrument (the Herpes Out-
break Impact Questionnaire) has been produced for
this purpose [17].
The Recurrent Genital Herpes Quality of Life
(RGHQoL) questionnaire [18] was with 1349
patients who had experienced a minimum of six
herpes outbreaks in the previous year. The mean
improvement in score on the RGHQoL of patients
on active therapy ranged from 9.4 to 12.0 from a
baseline of 30.2 to 33.9. Improvement in score in
the placebo group was 4.8 points from a baseline of
32.4. The study clearly showed the beneﬁts of ther-
apy on QoL.
In a subsequent study [19], the SF-36 and
RGHQoL were employed with 307 RGH patients.
Neither frequency of recurrences nor pain and dis-
comfort experienced during outbreaks inﬂuenced
scores on the SF-36. In contrast, RGHQoL scores
were signiﬁcantly related to both recurrence fre-
quency and severity of pain and discomfort during
recurrences.
 
Adult Growth Hormone Deﬁciency
 
One of the most widely used needs-based instru-
ments is the QoL-AGHDA (Quality of life—Assess-
ment in Growth Hormone Deﬁcient Adults [20])
despite the relatively low prevalence of the condi-
tion. This is due to the absence of clear clinical indi-
cators of disease severity.
Studies of growth hormone replacement in the
Netherlands  [21]  and  Spain  [22]  indicated  that
the QoL-AGHDA had greater responsiveness than
the Nottingham Health Proﬁle. A further study was
conducted to validate the Swedish version of the
QoL-AGHDA through the implementation of
Rasch analysis [23]. The study also sought to com-
pare the QoL of 111 adults with untreated GH deﬁ-
ciency with that of a reference population (1448
adult subjects randomly selected from the popula-
tion of Göteborg).
Most items in both samples were found to ﬁt
the Rasch model, conﬁrming the unidimensionality
of QoL-AGHDA. Overall, the hierarchical order of
the items from the two samples was similar,
although certain items performed differently in the
two samples. For example, “I have to force myself
to do all the things that need doing,” reﬂects more
severely impacted QoL for the reference sample
than for the patient sample. Examination of the per-
son’s QoL logit scores showed that these minor
inconsistencies had no overall effect on the results
obtained with the measure.
Data from the two populations showed signiﬁ-
cant differences, as determined by nonoverlapping
 
Table 1
 
Relation between severity of  depression and quality
of  life
 
Severity of  depression* Mean QLDS score
 
n
 
HDRS 
 
<
 
 4 (None) 1.5 15
HDRS 4–7 (Mild) 6.5 14
HDRS 8–20(Moderate) 12.6 163
HDRS 
 
>
 
 20(Severe) 21.8 79
 
*Hamilton Depression Rating Scale.
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conﬁdence intervals. Figures 1 and 2 show the mean
QoL-AGHDA scores for males and females, respec-
tively. These have been transformed by Rasch anal-
ysis to range from 0 to 100. This is the ﬁrst real
evidence that adults who are GH-deﬁcient have
inferior QoL to those without the deﬁciency. Indi-
cations from other studies using the QoL-AGHDA
are that substitution therapy improves the QoL of
deﬁcient adults up to the level expected for an aver-
age population.
This is also the ﬁrst occasion on which a disease-
speciﬁc questionnaire has been used to provide valid
comparisons between healthy and diseased popula-
tions. The fact that the two groups treat some items
differently partly explains why it is misleading to
use a generic health status measure for such a pur-
pose. As the scales of measures such as the NHP and
SF-36 fail to ﬁt the Rasch model, it is not possible to
establish that such comparisons, or indeed those
between patients with different diseases are valid.
Recently, the National Institute for Clinical
Excellence in the UK has reported on the use of
replacement growth hormone [24]. They recom-
mended that recombinant human growth hormone
(somatropin) treatment should be given to an adult
with GH deﬁciency only if he meets certain criteria;
one of which is that the individual has a score of at
least 11 on the QoL-AGHDA. Furthermore, an
adult who has been started on GH treatment should
be re-assessed for QoL status 9 months after the ini-
tiation of therapy. GH treatment should be discon-
tinued if the individual has a QoL improvement of
fewer than 7 points in QoL-AGHDA score. This is
the ﬁrst time that a QoL measure has been used to
determine whether or not treatment should be
given.
 
Conclusions
 
These studies suggest that needs-based QoL meas-
ures are more capable of detecting changes in level
of QoL associated with effective treatment than
existing measures commonly used in studies, when
used in the populations for which they were devel-
oped. Such responsiveness is a crucial quality of an
outcome measure. As these measures become more
widely used in trials it is anticipated that their value
will become more widely recognized.
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Mean QoL-AGHDA scores—Swedish males.
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Figure 2
 
Mean QoL-AGHDA scores—Swedish females.
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